『 YaBoyJ313 』

@RefinedTrader1 Even if they issue a CRL (sad to say it's probably what's most likely here), it's not the nail in the coffin. It's just another setback. It has happened to numerous other pharma/bios, and Neffy even had to go through the same path. Just sucks that it wasn't a slam dunk PDUFA.

$AQST folks settle down. Read, its not over till an actual CRL is issued.

youtube.com/watch?v=fKYrcF… Getting close to that time of year again!! :D

OutRun GB is OUT NOW for your Game Boy Color.🌴 - All the tracks, all the music, all the wind in your hair! (link in reply) #pixelart #indiedev #gameboy #retrogaming

Numpy’s fromfile()/tofile() make me smile — no typing or byte order metadata, they just write/read the raw bytes. A joyful API! I wish PyTorch had them natively on tensors, so I wasn’t doing so many tensor.cpu().numpy() operations.

The Kids Online Safety Act is the U.S. equivalent of the EU's Digital Services Act and the UK's Online Safety Act. If passed, it could mandate digital identity, fully deanonymize the internet, and impose significant censorship.

@blooprintgames @veys_el_kara @Gorliac1 @L3D00 Glad to see main channel content finally even though the wipes have been tough! Cheers Bloo!

I hired two anti-clan specialists to play one of the most competitive servers in Rust. And if that wasn't hard enough, we made it our goal to RAID everyone we could as just a trio. The results were CRAZY. GO WATCH NOW!! 🔥 📺 -> youtu.be/sBE2mHFP6uM 🎨-> @veys_el_kara

🚨 EXCLUSIVE: Arsenal & Sporting CP on verge of total agreement for Viktor Gyokeres. €63.5 + €10m already struck but add-ons needed work - now finishing touches, conclusion imminent. #SportingCP striker wanted #AFC only; 5yr contract ready @TheAthleticFC nytimes.com/athletic/64912…

Dear $OPEN Investors, Let’s break down what’s happening with Opendoor, especially for those who are newer to the market. Opendoor has approximately 729.13 million shares outstanding. That means just over 729 million shares actually exist and are held by investors. However, in a single recent trading session, we saw 1.66 billion shares traded. In plain terms, the entire share count turned over more than twice in one day. So how is that possible? Trading volume counts how many times shares change hands, not how many shares actually exist. If a single share is bought and sold multiple times in a day, each trade adds to the volume. Think of it like a game of hot potato one trader passes the share to another, who quickly passes it again, and again. The share might be flipped dozens of times in a single session, especially in a frenzy like this. Opendoor’s stock price ran from 51 cents to a high of $4.97 an 800 percent move — despite the company still being unprofitable. And just today, we saw 26.4 million shares traded in a single minute, which caused the price to collapse from $4.60 to $2.79 in real time. That kind of price action doesn’t come from long-term investors it comes from fast-moving speculation and algorithmic selling. Yesterday, we published a proprietary institutional analysis that revealed a concerning pattern: institutions have been systematically offloading shares into this rally. We reviewed 591 institutional transactions and found that many of the largest players are not taking profits they are cutting losses. Our model showed that institutions are selling in coordinated bands, with selling activity happening between $13 and $14, and significant activity even in the $3 to $4 range. This is not random behavior. It’s defensive selling a strategy to quietly exit risk positions while retail excitement drives price higher. The data is clear. Institutions like Renaissance Technologies, Morgan Stanley, and Goldman Sachs have liquidated over 35 million shares, and our analysis estimates over 23 million more shares are set to sell into the rally. That’s more than eight days' worth of average volume. Retail buying can’t absorb that kind of supply and institutions know it. We also calculated a Liquidity Absorption Ratio (LAR) of 865 percent at key resistance levels, which means it would take 8.65 full days of trading volume just to soak up institutional selling. That creates a price ceiling. Once the stock enters those zones, the math shows a high probability of reversal not continuation. Our modeling predicts less than a 10.4 percent chance that OPEN can reach and sustain prices above $14. The takeaway is simple. This rally isn't organic. It's driven by retail enthusiasm, while institutions use that volume as exit liquidity. If you’re buying here without understanding this structure, you’re essentially catching shares that smart money is trying to unload. This isn't speculation it’s a transfer of risk, and retail is on the receiving end.

$OPEN made a quick and easy 100% today. That end of day rug was brutal. Two pieces of advice for anyone playing these crazy pumps: 1. When the halts start coming, better start exiting 2. When new options chains open up, and premiums are sky high, it's over

@AscendingBio @Maximus_Holla Pending Anaphylm approval, partnership is a must. The necessary cash to support manufacturing, marketing, and salseforce is imperative if $AQST is to succeed in generating meaningful revenue. Either a partnership, or a full BO. The latter I see being less likely.

Libervant is not able to launch until early 2027 due to FDA issues. It should be 100 million a year after building awareness. I think estimates of 150 to 200 million are too high. With Anaphylm, the portability of this product changes everything. People do not want to carry around 2 devices everywhere they go. I hold that Anaphylm will dominate the epinephrine rescue medication market about 1.5 to 2 years after approval. Numbers like 85% market share are quite possible. My conservative price target at approval is $15. Yet, it could go higher. There is also a good case for holding the stock after approval. If they achieve market dominance, there is plenty of room for this to rise. This market dominance could start to impact big markets beyond the US. The wildcard is their topical gels that are in development. This product line has the potential to exceed Anaphylm revenue. In summary, if Anaphylm is approved by the FDA, a big payday is coming. Yet, there may be even larger ones after that.

@Maximus_Holla Have you checked out $AQST? Lead drug Anaphylm PDUFA date of Jan 31, 2026. Forward rev projections of $790M - $1B. Competator $SPRY $9 -> $18 after FDA approval. My conservative PT is $17 on approval. Thoughts?

@AscendingBio @Maximus_Holla Partially correct. It's not due to FDA issues, it's due to ODE designation on a previously approved drug. Libervant was given ODE once the current drug expires in 2027, and then Libervant will be available for US market.

$open insanity. Gonna splash some cash on OTM's on Monday. Hopefully the volume keeps doing it's thing for whatever reason.

i cannot lie this goes INSANELY hard

I'm making a portable GameCube. It's not a Wii. It'll have a directly driven 480p laminated IPS panel for the crispiest GameCube pixels you've seen. It'll have USB C PD charging. Video out over USB C. Wireless 4 player multiplayer. Oh, it'll play Gameboy games too.

@RawuRust Waiting on bro for SoundCloud / mp3 drop like…

@J313Ya Ill look into it.

@RawuRust brother, I need the name of the first song in the latest Riqqeloff video! That beat is so funky and groovy. I need to play it on loop while I work. GG's! Thanks! youtube.com/watch?v=PcmR4z…

Mikel Arteta and Berta want to pay 60M for this but can’t add 5M to finalize Viktor Gyökeres deal. Is Arsenal cursed or it was meant to torture us forever ⁉️ #SayNoToMadueke #NoToMadueke

Some Arsenal fans seem to be losing patience with Mikel Arteta 😳 Murals outside the Emirates have been vandalized with "Arteta Out" messages 👀